HC Wainwright reiterates Neutral on Lipocine, $4 target
HC Wainwright & Co. reiterated a Neutral rating on Lipocine, setting a $4.00 price target. The target implies 81.0% upside versus the Sep 18 close of $2.21.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.